文献速递炎症性肠病胃肠动力与功能性疾病

罗马IV标准下溃疡性结肠炎患者大便失禁的患病率与负担:一项横断面研究

The prevalence and burden of Rome IV faecal incontinence in ulcerative colitis: A cross-sectional study.
PubMed 文献 · Aliment Pharmacol Ther · 2023-04-03

本研究为前瞻性横断面研究,纳入255例溃疡性结肠炎(UC)患者,采用罗马IV标准评估大便失禁(FI)。20.4%的患者符合罗马IV的FI标准,且活动期与静止期患病率无显著差异。多数患者在「缓解期」(75.2%)和「复发期」(90.6%)报告FI,合并FI者焦虑、抑郁评分更高、生活质量更差。

要点

  • 255例UC患者中20.4%符合罗马IV的FI标准
  • 活动期与静止期FI患病率无显著差异(p=0.25、0.86、0.95)
  • 合并FI者焦虑、抑郁更高且生活质量更差(p<0.05)

核心结论

  • UC患者中FI患病率高,即使在缓解期也存在,并与显著心理困扰、症状负担及生活质量受损相关。
  • 上述发现突显了进一步研究和开发UC相关FI循证治疗的迫切需求。

研究设计与样本

  • 前瞻性横断面研究,纳入255例溃疡性结肠炎患者,完成包括罗马IV FI标准、IBD特异性FI问卷(ICIQ-IBD)、医院焦虑抑郁量表和IBD-Control在内的系列验证问卷。
  • UC缓解定义为粪钙卫蛋白(FCP)≤250 μg/g,或IBD-Control 8评分≥13且IBD-Control-VAS≥85。

主要发现

  • 255例UC患者中,总体20.4%符合罗马IV的FI标准。
  • 无论以IBD-Control评分±FCP(p=0.25)、FCP阈值250 μg/g(p=0.86)还是100 μg/g(p=0.95)定义疾病活动度,活动期与静止期UC的罗马IV FI患病率均无差异。
  • 据ICIQ-IBD,多数患者报告在「缓解期」(75.2%)和「复发期」(90.6%)出现FI。
  • 同时符合ICIQ-IBD和罗马IV FI定义者焦虑、抑郁评分更高、生活质量(QoL)评分更差(p<0.05)。
  • 在符合罗马IV FI者中,FI症状严重程度与生活质量受损呈强相关(r=0.809,p<0.001)。

关键数值与推荐

  • UC缓解定义为FCP≤250 μg/g,或IBD-Control 8评分≥13且IBD-Control-VAS≥85。
  • 255例中20.4%符合罗马IV的FI标准。
  • ICIQ-IBD报告缓解期FI为75.2%、复发期FI为90.6%。
  • 罗马IV FI者中FI症状严重程度与QoL受损相关(r=0.809,p<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite advances in ulcerative colitis (UC) therapies, a relatively undefined proportion of patients experience faecal incontinence (FI) in the absence of active inflammation. For this group, there remains a significant unmet need with a limited evidence base. AIMS: We aimed to estimate the prevalence and impact of FI in UC. METHODS: In a prospective cross-sectional study, patients with UC completed a series of validated questionnaires, including Rome IV FI criteria, an inflammatory bowel disease (IBD)-specific FI questionnaire (ICIQ-IBD), Hospital Anxiety and Depression Scale and IBD-Control. UC remission was defined as faecal calprotectin (FCP) ≤250 μg/g, or IBD-control 8 score ≥13 and IBD-Control-VAS ≥ 85. RESULTS: Of 255 patients with UC, overall, 20.4% fulfilled Rome IV criteria for FI. Rome IV FI prevalence did not differ between active and quiescent UC regardless of whether disease activity was defined by IBD-Control scores ± FCP (p = 0.25), or objectively with FCP thresholds of 250 μg/g (p = 0.86) and 100 μg/g (p = 0.95). Most patients (75.2%) reported FI when in 'remission' and during 'relapse' (90.6%) according to ICIQ-IBD. Those who reported FI according to both ICIQ-IBD and Rome IV definitions had higher anxiety, depression and worse quality-of-life (QoL) scores (p < 0.05). In those with Rome IV FI, there was a strong correlation between FI symptom severity and impaired QoL (r = 0.809, p < 0.001). CONCLUSIONS: The prevalence of FI in UC is high, even in remission, and associated with significant psychological distress, symptom burden and impaired QoL. These findings highlight the urgent need for further research and development of evidence-based treatments for FI in UC.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Vasant DH, Nigam GB, Bate S, et al. The prevalence and burden of Rome IV faecal incontinence in ulcerative colitis: A cross-sectional study. Aliment Pharmacol Ther. 2023. PMID: 37012703. doi:10.1111/apt.17502

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。